Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILP100-DP for Diabetic Foot Ulcers (Phase 2a)
2021-000563-69Phase 2Terminated
- Sponsor
- Ilya Pharma
- Start
- Mar 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing ILP100-DP with Placebo (2 arms). Primary endpoint: Safety (AE/SAE incidence and categories). Started Mar 2021; status: terminated.
02
Drugs
emilimogene sigulactibac
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2021-000563-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000563-69.